Login
Contact

Explore

Explore

About
  • People and Partners
  • TRI Building
  • Reconciliation Action Plan
  • Strategic Plan
  • TRI Foundation
  • Careers
Research
  • Collaborate
  • Discovery
  • Translate
  • Engage
  • Research Areas
Clinical
  • Translational Trials
  • Clinical Research Facility
  • TRI at Children’s
Industry
  • TRI Incubator
  • The Precinct
  • Residents
Manufacture
  • New cGMP Facility
Facilities
  • Cleanroom
  • Flow Cytometry
  • Histology
  • Microscopy
  • Proteomics
  • Preclinical Imaging
  • Biological Research
  • Gnotobiotics
  • Human Immune Model
Get Involved
  • Health Consumers
  • SPARQ-ed
Resources
  • News
  • Events
  • Case Studies
  • Grants and Funding
  • Education and Training

+61 7 3443 7000info@tri.edu.au37 Kent Street, Woolloongabba QLD 4102 Australia

Acknowledgement of Country

TRI acknowledges the traditional custodians of the land we are on today, the Turrbal and Jagera people and we recognise their continuing connection to land, waters and community. We pay deep respect to them and their cultures; and to Elders past, present and emerging.

© Translational Research Institute Pty Ltd atf the Translational Research Institute Trust|ABN: 58 155 991 662
Privacy policy|Terms of Use|Contact Us
TRI · TM@TRI

TM@TRI

2021
2022
2023
2024
2025

Countdown to 2026

TRI’s translational manufacturing facility will become Australia’s first scale-up biomedical cGMP facility for maturing, high-potential, biomedical startups.

This world-class facility will enable companies to manage their own product manufacturing and commercialisation pathways, preserving their intellectual property 
and know-how.

Our unique cGMP model will provide expertise, specialist equipment and resourcing to support delivery of new diagnostics, medical devices and therapies with real-world impacts.

$100m+ investment

funded by the Queensland Government and TRI

 

High pre-opening occupancy demand

 

$37M invested in world class state-of-the-art equipment

500

highly skilled science jobs

 


on campus at a tertiary teaching hospital in a thriving innovation precinct

What will TM@TRI mean to medical research in Australia?

“It’s going to have an amazing mix of capabilities, from manfacturing to lab space, to offices… having options like this coming online is exciting for Queensland companies.”
Professor Trent Munro

Senior VP Therapeutics, Microba

“TM@TRI is very exciting because it means that we'll be able to take basic science through to translational research, and then actually go ahead and manufacture with a view to getting it back into the clinic, which is really what it's all about.”
Emeritus Professor Ian Frazer

Co-Founder Gardasil HPV Vaccine

"If you're a biotech or medtech, innovator or inventor, you have the capacity now to go from incubation through to producing your clinical material for initial trials, to manufacturing the commercial grade material you need for your later stage trials all in one place."
David Hoey

President and CEO, Vaxxas

Discover a new home for translational manufacturing

Retaining Australian bio-tech start ups

TM@TRI provides an opportunity to for local biomed companies to base their manufacturing here in Queensland rather than needing to go offshore.

Thriving life sciences hub

Connections to government and regulatory bodies, industry and the life sciences sector.

Size and scale

TM@TRI will add four floors (7,000m2) to TRI’s existing footprint, making this the largest end-to-end translational research facility of its kind in Australia.

Within the Boggo Road Innovation Precinct

Home to a growing ecosystem of talent forging collaborations locally and globally.

Accessible support

Reducing barriers to entry through specialist expertise not generally accessible to start-ups.

Navigate TM@TRI

Collaboration space

Innovation and collaboration spaces for engineering and chemistry; pitch and event spaces
Level 1
 
Level 2
 
Level 3
 
Level 4

Services

  • In-house Quality Assurance (QA) team with validated Quality Management System (QMS) framework.
  • Facilitation of Raw Material, Incoming Goods and Final Product disposition management.
  • Tenant equipment implementation, commissioning, qualification, validation and calibration support.
  • Controlled Raw Material & Final Product storage (RT, 2-8°C, -70°C & cryo-storage).
  • Shared space facility cleaning, maintenance and environmental monitoring.
  • Core facility cGMP equipment maintenance and support (eg. autoclave).
  • Waste routing and management.
  • Supply chain and logistical support.
  • cGMP consultancy and training.
Anchor Tenant

Translational Science Hub claims space

TM@TRI will be home to the $280M Translational Science Hub, linking Queensland researchers with Sanofi scientists in France and the US.

The unique global research and development network will initially focus on the evaluation of a new generation of mRNA vaccines and the development of a world-first chlamydia vaccine.

The hub will deliver 200 new highly-skilled science, research and healthcare jobs, along with increased pathways for young people entering the biomedical sector.

Sanofi-logo

 

Anchor Tenant

Translational Science Hub claims space

TM@TRI will be home to the $280M Translational Science Hub, linking Queensland researchers with Sanofi scientists in France and the US.

The unique global research and development network will initially focus on the evaluation of a new generation of mRNA vaccines and the development of a world-first chlamydia vaccine.

The hub will deliver 200 new highly-skilled science, research and healthcare jobs, along with increased pathways for young people entering the biomedical sector.

Sanofi-logo

 

Enter your details to receive more information.